Prescription patterns of lipid lowering agents among older patients in general practice: an analysis from a national database in the Netherlands.
Sign Up to like & getrecommendations! Published in 2019 at "Age and ageing"
DOI: 10.1093/ageing/afz034
Abstract: BACKGROUND Dutch cardiovascular risk management guidelines state almost every older adult (≥70 years) is eligible for a lipid lowering drug (LLD). However, life expectancy, frailty or comorbidities may influence this treatment decision. OBJECTIVE investigate how… read more here.
Keywords: aged years; age; lld prescriptions; frailty ... See more keywords
247-OR: Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-247-or
Abstract: Both SGLT2i inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) have shown cardiovascular (CV) benefits in CV outcome trials among patients with type 2 diabetes (T2D) and established CV disease (CVD). Whether these agents are… read more here.
Keywords: patients without; receptor agonists; research support; glp receptor ... See more keywords
In at-risk patients without CVD, polypill plus aspirin reduced a composite of major CV events at 4.6 y
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Internal Medicine"
DOI: 10.7326/acpj202104200-041
Abstract: SOURCE CITATION Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384:216-28. 33186492. read more here.
Keywords: patients without; plus aspirin; risk patients; cvd polypill ... See more keywords